CTRI/2023/03/050407尚未招募2 期
A randomized, parallel group, open label, Standard controlled clinical study toCompare the efficacy and safety of unani Pharmacopoeial Formulation Jawarish Kundur with Oxybutynin in cases of Kathra al-Bawl (Overactive Bladder)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •History of all or any of the following symptoms for more than six months
- •1. Urgency of urine
- •2. Incontinence
- •3. Frequency
- •4. Nocturia
排除标准
- •The following patients will be excluded from the study
- •1.Patients with history of Bladder calculus
- •2.Patients with Urinary tract infections
- •3.Known case of Benign Prostrate Hypertrophy
- •4.Known case of Uterine prolapse
- •Patients with Rectocele/cystocele
- •Patients with Cystitis
- •Pregnant and lactating females
- •Known case of Neoplasm
- •Known case of with Hepatic/Cardiac diseases
- •Known case of Multiple sclerosis and Spinal cord injury.
- •Medications (anticholinergic, antidepressant, psychotropic, or alpha-blocker)
研究者
相似试验
尚未招募
2 期
A Clinical Study to assess Effectiveness of Unani formulations in pityriasis versicolorCTRI/2020/06/026209ational Research Institute of Unani Medicine for Skin Disorders Hyderabad
尚未招募
2 期
Evaluating Efficacy of Unani Formulation in TineaCTRI/2021/08/036043ational Research Institute of Unani Medicine for Skin Disorders
已完成
不适用
comparison of potassium hydroxide and podophyllotoxin in the treatment of molluscum contagiosumCTRI/2018/08/015198Dr Niharika Ranjan Lal40
进行中（未招募）
不适用
A Randomized, Open Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer who have Previously Received Platinum Based Chemotherapy - INTERESTocally Advanced or Metastatic Recurrent Non-Small Cell Lung CancerEUCTR2004-002943-28-LVAstraZeneca AB1,440
尚未招募
3 期
se of HYDRODENG SACHET in Dengue fever patientsCTRI/2024/04/065599Tirupati Medicare Limited, India.